Deepwatch Named to CRN's 2025 Security 100 List
SAN FRANCISCO, March 25, 2025--(BUSINESS WIRE)--Deepwatch, the leading AI+Human cyber resilience platform, today announced its inclusion in CRN® 's prestigious Security 100 list in the Endpoint and Managed Security category. This annual list recognizes leading IT security vendors that collaborate with channel partners to safeguard businesses from ever-evolving cyber threats.
Deepwatch operates at the forefront of cybersecurity, tackling the reality that companies must protect 100% of their growing attack surface. With the increasing adoption of cloud infrastructure, expansion of hybrid work models, and rapid growth in digital commerce, businesses face an average of 40,000 security alerts every workday, weekend, and holiday. Threats exist 24/7/365, requiring an advanced approach to security operations.
Leveraging security and business analytics, holistic expert systems enriched by dedicated AI technologies, validated and prioritized by a dedicated "eyes-on-glass" team, Deepwatch democratizes AI-driven security, ensuring accessibility for organizations of all sizes. As cyber threats continue to evolve at an unprecedented pace – with hacker dwell times shrinking from 90 days to just 90 minutes – Deepwatch's comprehensive security platform keeps businesses ahead of the curve, strengthening their cyber resilience.
"At Deepwatch, we recognize that cyber resilience is critical in today's rapidly shifting threat landscape," said John DiLullo, CEO of Deepwatch. "We are honored to be named to CRN's Security 100 list, which underscores our commitment to equipping organizations with the AI-powered solutions, expert-driven insights, and comprehensive security strategies they need to stay ahead of adversaries."
Now in its 10th year, CRN's Security 100 list honors channel-focused security vendors across five key technology categories: Endpoint and Managed Security; Identity, Access and Data Security; Network Security; Security Operations, Risk and Threat Intelligence; and Web, Email, and Application Security.
"Each company on the Security 100 list provides cutting-edge security offerings through solution providers in the IT channel," said Jennifer Follett, Vice President, U.S. Content and Executive Editor, CRN, at The Channel Company. "Robust cybersecurity is essential for modern businesses, and these vendors are committed to keeping their security portfolios ahead of bad actors and emerging threats. We congratulate them and look forward to seeing how they advance cybersecurity innovations in the future."
The 2025 Security 100 list is featured in the February 2025 issue of CRN and online at www.crn.com/security100.
For more information, visit www.deepwatch.com.
About Deepwatch
Deepwatch® is the pioneer of AI-and human-driven cyber resilience. The Deepwatch Platform enables lean security teams—regardless of skill level—to enhance their organization's cyber resilience and maintain regulatory compliance. By combining AI, security data, intelligence, and human expertise, Deepwatch helps organizations reduce risk through early and precise threat detection and remediation. The platform also lowers costs, maximizes existing tool investments, and enhances security team productivity. For more information about Deepwatch, visit www.deepwatch.com.
"Deepwatch" is a trademark of Deepwatch, Inc. and its subsidiaries. All other trademarks, trade names, service marks, and logos referenced herein belong to their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325358095/en/
Contacts
Media: ICR for DeepwatchSena McGranddeepwatch@icrinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
What the UK's Emergency Services Can Teach Startups About AI That Actually Works -- New Report from Speechmatics
New report reveals how Voice AI is quietly transforming frontline response while others scale back CAMBRIDGE, England, June 03, 2025--(BUSINESS WIRE)--While many "AI-first" launches have fizzled, emergency services are showing what it really means to put AI to work. A new report from Speechmatics reveals that 100% of UK ambulance calls now run through Voice AI infrastructure. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report explores how speech systems are quietly transforming high-pressure environments like triage, crisis response and public service contact centres. Forget avatars and demos — real-world adoption is being driven by accuracy, speed, and reliability. Key findings include: Full Voice AI coverage across UK ambulance services 40% clinician time reclaimed in public healthcare settings 93% satisfaction using voice-led systems in utilities Hybrid deployments (on-prem, cloud, edge) now expected as standard Speech AI technology sits behind these critical deployments — enabling real-time transcription, multilingual support, and data privacy at scale. As enterprises rethink their AI strategies, this report highlights the sectors already making it work — and what others can learn from them. Download the full report now. View source version on Contacts For interviews, images, quotes or media access, contact: Mieke Kyra, Content Lead Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
"AI-First" Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI
CAMBRIDGE, UK, June 03, 2025--(BUSINESS WIRE)--After a wave of bold "AI-first" announcements from major tech players, many are now scaling back. As the AI gold rush slows, a new report from Speechmatics explores what's actually working — and where the real value lies. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report zeroes in on one of the fastest-evolving areas of AI: Voice AI. Built on interviews with leaders across healthcare, compliance, media, public services, and research, it reveals a clear shift from flashy demos to embedded, operational AI — where tools assist humans, deliver measurable ROI, and quietly power core infrastructure. Report highlights include: Assistive over autonomous: The most effective deployments augment people rather than replace them. Assistive agents are driving real ROI. Multilingual as standard: Real-time code-switching is now a baseline requirement, not a bonus. Accuracy is make-or-break: With growing global concerns over AI hallucinations, precision is essential — especially in compliance-heavy environments. Voice as infrastructure: Quietly embedded tools are outperforming headline-grabbing features. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. It's being embedded into workflows that demand speed, accuracy, and trust — from noisy control rooms to multilingual contact centres. The report closes with future-looking predictions, outlining the rise of emotionally intelligent, adaptive, and natively multilingual voice systems — and offers guidance on what enterprises must prioritise next. Download the full report now. View source version on Contacts For interviews, images, quotes or media access, contact: Mieke Kyra, Content Lead
Yahoo
25 minutes ago
- Yahoo
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
LEIDEN, Netherlands, June 09, 2025--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. "We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders," said Stefano Portolano, CEO at Azafaros. "With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need." About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Sign in to access your portfolio
